Cardiopulmonary bypass technology transfer: musings of a cardiac surgeon.
The development of cardiopulmonary bypass (CPB) has been one of the greatest technical advancements in cardiovascular medicine. With heparin anticoagulation, this device can safely replace the circulatory and gas-exchanging functions of the heart and lung, facilitating complex cardiac operations. Limitations still exist however, related to blood reactions at the biomaterial surface, such as cell activation, inflammation and low-grade thrombosis. In this brief review, the thought processes which paralleled the development of CPB biocompatible surfaces such as heparin-coating, will be explored, as well as current theories on the suspected mechanisms by which heparin-coated surfaces act as an anti-inflammatory device during CPB. Results with new surfaces for CPB designed to capitalize on superior protein adsorption properties, such as surface modifying additive (SMA) and poly (2-methoxyethylacrylate) (PMEA), will also be described. Finally, the significance of biomaterial-independent blood activation will be discussed, emphasizing the current need to develop strategies utilizing optimal biomaterials, modified surgical technique and pharmacologic therapy to minimize the systemic complications of CPB.
Rubens
F D
FD
Ottawa Heart Institute, Ontario, Canada. frubens@ottawaheart.ca
D001777:Blood Coagulation; D001798:Blood Proteins / Q000378:metabolism; D002315:Cardiopulmonary Bypass / Q000009:adverse effects / Q000295:instrumentation*; D020099:Coated Materials, Biocompatible / Q000592:standards*; D006801:Humans; D013499:Surface Properties; D013927:Thrombosis / Q000209:etiology / Q000517:prevention & control
D001798:Blood Proteins; D020099:Coated Materials, Biocompatible